The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): Current status and future opportunities

Expert Opinion on Investigational Drugs

Volumn 19, Issue 2, 2010, Pages 295-304

  Head, Michelle ^a   Jameson, Michael B ^a  

^a WAIKATO HOSPITAL   (New Zealand)

Author keywords

5,6 dimethylxanthenone 4 acetic acid; AS1404; ASA404; DMXAA; Tumor vascular disrupting agent; Tumor vasculature; Vadimezan

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOFLAXONE; PACLITAXEL; PLACEBO; TIRAPAZAMINE; VINCRISTINE;

ADVANCED CANCER; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; AREA UNDER THE CURVE; BLOOD PRESSURE; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CLINICAL TRIAL; CONFUSION; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; EYE TOXICITY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; INJECTION SITE PAIN; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PULSE RATE; QT PROLONGATION; REVIEW; SIDE EFFECT; SLURRED SPEECH; SWEATING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TASTE DISORDER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; URINE INCONTINENCE; UTERINE CERVIX CARCINOMA; VISUAL DISORDER;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; XANTHONES;

EID: 74549118938     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903540214     Document Type: Review

References (71)

1. Denekamp J, Hill S. Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol 1991;20(Suppl 1):103-112
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31
3. Okines A, Cunningham D. Current perspective: bevacizumab in colorectal cancer: a time for reappraisal? Eur J Cancer 2009;45:2452-2461
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550 (Pubitemid 44917502)
5. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-1234
6. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004;100:2491-2499
7. Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer 2007;96:1159-1165
8. Lippert JW III. Vascular disrupting agents. Bioorg Med Chem 2007;15:605-615
9. Kerr DJ, Kaye SB. Flavone acetic acid-preclinical and clinical activity. Eur J Cancer Clin Oncol 1989;25:1271-1272
10. Chabot GG, Branellec D, Sassi A, et al. Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouse. Eur J Cancer 1993;29:729-733
11. Haworth C, O'Reilly SM, Chu E, et al. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III. Cytokine studies. Br J Cancer 1993;67:1346-1350
12. Ching LM, Finlay GJ, Joseph WR, Baguley BC. In vitro methods for screening agents with an indirect mechanism of antitumour activity: xanthenone analogues of flavone acetic acid. Eur J Cancer 1991;27:1684-1689
13. Rewcastle GW, Atwell GJ, Baguley BC, et al. Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the Colon 38 tumor in vivo. J Med Chem 1989;32:793-799
14. Philpott M, Joseph WR, Crosier KE, et al. Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 1997;76:1586-1591
15. Philpott M, Ching LM, Baguley BC. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor. Eur J Cancer 2001;37:1930-1937
16. Bibby MC, Double JA, Phillips RM, Loadman PM. Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). Br J Cancer 1987;55:159-163
17. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). J Natl Cancer Inst 1989;81:1005-1013
18. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. The morphological effects of the anti-tumour agents flavone acetic acid and 5,6-dimethylxanthenone acetic acid on the colon 38 mouse tumour. Pathology 1994;26:161-169
19. Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001;77:195-204
20. Baguley BC, Ching LM. Immunomodulatory actions of xanthenone anticancer agents. BioDrugs 1997;8:119-127
21. Desoize B, Carpentier Y, Guerrier D. Response of primary tumour, spontaneous metastases and recurrence of lewis lung carcinoma (3LL) to flavone acetic acid (FAA, LM975). Anticancer Res 1989;9:1701-1705
22. Bibby MC, Phillips RM, Double JA. Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512). Cancer Chemother Pharmacol 1989;24:87-94
23. Lash CJ, Li AE, Rutland M, et al. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998;78:439-445
24. Ching LM, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 2004;90:906-910
25. Ching LM, Cao Z, Kieda C, et al. Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br J Cancer 2002;86:1937-1942
26. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-148
27. Kestell P, Zhao L, Jameson MB, et al. Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin Chim Acta 2001;314:159-166
28. Zhao L, Ching LM, Kestell P, et al. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): increased tumor vascular permeability. Int J Cancer 2005;116:322-326
29. Joseph WR, Cao Z, Mountjoy KG, et al. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 1999;59:633-638
30. Zhao L, Ching LM, Kestell P, Baguley BC. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 2002;87:465-470
31. Ching LM, Goldsmith D, Joseph WR, et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6- dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 1999;59:3304-3307
32. Jassar AS, Suzuki E, Kapoor V, et al. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 2005;65:11752-11761
33. Baguley BC, Ching LM. DMXAA: an antivascular agent with multiple host responses. Int J Radiat Oncol Biol Phys 2002;54:1503-1511
34. Siim BG, Lee AE, Shalal-Zwain S, et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003;51:43-52
35. Green C, Djeha H, Ireson C, Kelland LR. Consistent marked potentiation of the in vivo antitumor activity of taxanes by the vascular disrupting agent, DMXAA, in lung, ovarian and prostate cancer xenografts. AACR Meeting Abstracts; 2006. p. 121-c
36. Wilson WR, Li AE, Cowan DS, Siim BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 1998;42:905-908
37. Siemann DW, Horsman MR. Enhancement of radiation therapy by vascular targeting agents. Curr Opin Investig Drugs 2002;3:1660-1665
38. Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4- acetic acid. Radiat Res 2001;156:503-509
39. Murata R, Overgaard J, Horsman MR. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2001;17:508-519
40. Webster LK, Ellis AG, Kestell P, Rewcastle GW. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver. Drug Metab Dispos 1995;23:363-368
41. Miners JO, Valente L, Lillywhite KJ, et al. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res 1997;57:284-289
42. Zhou S, Paxton JW, Tingle MD, et al. Determination of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1999;734:129-136
43. Zhou S, Kestell P, Baguley BC, Paxton JW. Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol 2003;65:109-120
44. Zhou S, Chin R, Kestell P, et al. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. Br J Clin Pharmacol 2001;52:129-136
45. McKeage MJ, Kestell P, Denny WA, Baguley BC. Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemother Pharmacol 1991;28:409-413
46. Kestell P, Paxton JW, Rewcastle GW, et al. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4- acetic acid in the mouse, rat and rabbit. Cancer Chemother Pharmacol 1999;43:323-330
47. Zhao L, Kestell P, Ching LM, Baguley BC. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. Cancer Chemother Pharmacol 2002;49:20-26
48. Zhou S, Paxton JW, Kestell P, Tingle MD. Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species. J Pharm Pharmacol 2001;53:463-471
49. Jameson MB, Thompson PI, Baguley BC, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003;88:1844-1850
50. Rustin GJ, Bradley C, Galbraith S, et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003;88:1160-1167
51. McKeage MJ, Fong P, Jeffery M, et al. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 2006;12:1776-1784
52. Jameson MB, Sharp DM, Sissingh JI, et al. Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials. Invest Ophthalmol Vis Sci 2009;50:2553-2559
53. Jameson MB, Baguley BC, Kestell P, et al. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial. Cancer Chemother Pharmacol 2007;59:681-687
54. Galbraith SM, Rustin GJ, Lodge MA, et al. Effects of 5,6- dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-3840
55. Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997;39:541-546
56. Horsman MR, Murata R, Overgaard J. Improving conventional cancer therapy by targeting tumour vasculature. Br J Cancer 1999;80:90(P247)
57. Wilson WR, Baguley B. Combination of the antivascular agent DMXAA with radiation and chemotherapy. Int J Radiat Oncol Biol Phys 2000;463:706
58. McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-2012
59. McKeage MJ, Reck M, Jameson MB, et al. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/ DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009;65:192-197
60. McKeage MJ, Jameson MB, AS1404-201 Study Group Investigators. Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404). J Clin Oncol 2008;26(20s):abstract 8072
61. Gabra H, AS1404-202 Study Group Investigators. Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer. J Clin Oncol 2006;24(20s):abstract 5032
62. Pili R, Rosenthal M, AS1404-203 Study Group Investigators. Randomized phase II study of docetaxel with or without DMXAA (AS1404) in hormone-refractory metastatic prostate cancer (HRMPC). J Clin Oncol 2008;26(20s):abstract 5007
63. Rehman F, Rustin G. ASA404: update on drug development. Expert Opin Investig Drugs 2008;17:1547-1551
64. Wu J, Long Q, Xu S, Padhani AR. Study of tumor blood perfusion and its variation due to vascular normalization by anti-angiogenic therapy based on 3D angiogenic microvasculature. J Biomech 2009;42:712-721
65. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92:1599-1610
66. Denekamp J. The current status of targeting tumour vasculature as a means of cancer therapy: an overview. Int J Radiat Biol 1991;60:401-402
67. De Raeve H, Van Marck E, Van Camp B, Vanderkerken K. Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies. Histol Histopathol 2004;19:935-950
68. Laubach JP, Mahindra A, Mitsiades CS, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009;23:2222-2232
69. Cao Z, Joseph WR, Browne WL, et al. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1999;80:716-723
70. Zhao L, Ching LM, Kestell P, Baguley BC. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4- acetic acid by optimal scheduling. Clin Cancer Res 2003;9:6545-6550
71. Wang LC, Ching LM, Paxton JW, et al. Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs. Invest New Drugs 2009;27:280-284